Zacks Small Cap Weighs in on Brainstorm Cell Therapeutics Inc.’s Q1 2024 Earnings (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for Brainstorm Cell Therapeutics in a research report issued on Thursday, April 11th. Zacks Small Cap analyst D. Bautz anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarter. The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($0.47) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.07) EPS and FY2026 earnings at ($0.24) EPS.

Separately, StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics in a research report on Wednesday, March 27th. They set a “sell” rating on the stock.

Brainstorm Cell Therapeutics Trading Down 6.0 %

NASDAQ BCLI opened at $0.55 on Monday. The company’s fifty day simple moving average is $0.45 and its 200-day simple moving average is $0.31. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $3.37. The stock has a market cap of $37.50 million, a P/E ratio of -1.34 and a beta of 0.27.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BCLI. JPMorgan Chase & Co. lifted its position in shares of Brainstorm Cell Therapeutics by 27.5% during the first quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock worth $827,000 after purchasing an additional 53,036 shares in the last quarter. State Street Corp increased its stake in shares of Brainstorm Cell Therapeutics by 10.8% in the first quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock worth $323,000 after buying an additional 9,357 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the second quarter worth $47,000. Virtu Financial LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the second quarter worth $57,000. Finally, Jane Street Group LLC bought a new stake in shares of Brainstorm Cell Therapeutics in the second quarter worth $33,000. 14.33% of the stock is owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.